

1. Sales January to September 2009 and 2008

	2009	2008	% change	
	CHF m	CHF m	In CHF	In local currencies
January – September				
Pharmaceuticals Division	29,034	26,193	+11	+12
Europe/Rest of World	14,387	13,869	+4	+13
US	11,157	10,090	+11	+6
Japan	3,490	2,234	+56	+34
Diagnostics Division	7,365	7,112	+4	+8
Roche Group	36,399	33,305	+9	+11

2. Quarterly local sales growth by Division in 2008 and 2009

	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008
Pharmaceuticals Division	+5	+8	+14	+15
Europe/Rest of World	+10	+8	+14	+17
US	0	+1	+12	+4
Japan	+5	+40	+16	+46
Diagnostics Division	+9	+8	+7	+10
Roche Group	+6	+8	+12	+14

3. Quarterly sales by Division in 2008 and 2009

CHF millions	Q3 2008	Q4 2008	Q1 2009	Q2 2009	Q3 2009
Pharmaceuticals Division	8,936	9,768	9,216	9,888	9,930
Europe/Rest of World	4,637	4,727	4,491	4,913	4,983
US	3,517	3,939	3,586	3,930	3,641
Japan	782	1,102	1,139	1,045	1,306
Diagnostics Division	2,365	2,544	2,361	2,541	2,463
Roche Group	11,301	12,312	11,577	12,429	12,393

4. Top 20 Pharmaceuticals Division product sales and local growth¹ in YTD September 2009: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	4,684	26%	2,544	18%	284	90%	1,856	33%
MabThera/Rituxan	4,606	8%	2,312	5%	177	4%	2,117	11%
Herceptin	3,972	9%	1,207	4%	257	36%	2,508	10%
Tamiflu	2,004	362%	506	34%	651	3186%	847	1753%
CellCept	1,289	-14%	515	-30%	37	13%	737	1%
Pegasys	1,280	11%	317	10%	96	22%	867	10%
NeoRecormon/Epogin	1,180	-9%	-	-	377	-2%	803	-12%
Tarceva	962	10%	379	1%	48	30%	535	16%
Xeloda	952	11%	355	14%	52	35%	545	7%
Lucentis	869	21%	869	21%	-	-	-	-
Bonviva/Boniva	780	2%	423	-13%	-	-	357	25%
Xolair	470	11%	470	11%	-	-	-	-
Valcyte/Cymevene	422	7%	209	10%	-	-	213	5%
Pulmozyme	373	7%	224	9%	-	-	149	3%
Activase/TNKase	333	32%	300	35%	-	-	33	8%
Nutropin	311	-1%	303	-1%	-	-	8	-4%
Xenical	307	-13%	27	-28%	-	-	280	-11%
Neutrogen	289	-15%	-	-	289	-15%	-	-
Rocephin	237	-5%	1	-67%	48	-2%	188	-5%
Madopar	211	-2%	-	-	17	4%	194	-2%

¹ versus YTD September 2008

5. Top 20 Pharmaceuticals Division quarterly local product sales growth in 2008 and 2009

	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008
Avastin	36%	30%	29%	21%
MabThera/Rituxan	16%	6%	10%	7%
Herceptin	12%	11%	10%	8%
Tamiflu	-65%	38%	1048%	887%
CellCept	11%	7%	-21%	-26%
Pegasys	5%	9%	10%	13%
NeoRecormon/Epogin	-8%	-13%	-8%	-7%
Tarceva	19%	13%	7%	11%
Xeloda	12%	8%	14%	11%
Lucentis	19%	21%	21%	21%
Bonviva/Boniva	23%	3%	2%	0%
Xolair	13%	13%	11%	9%
Valcyte/Cymevene	9%	7%	6%	7%
Pulmozyme	14%	3%	8%	8%
Activase/TNKase	13%	45%	17%	34%
Nutropin	-1%	1%	2%	-6%
Xenical	-11%	-14%	-10%	-14%
Neutrogen	-13%	-22%	-13%	-10%
Rocephin	-6%	-15%	2%	-2%
Madopar	3%	0%	-5%	1%

6. Pharmaceuticals Division quarterly local product sales growth US in 2008 and 2009

	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008
Avastin	21%	18%	22%	13%
MabThera/Rituxan	15%	6%	6%	1%
Herceptin	3%	0%	12%	1%
Tamiflu	-83%	-94%	710%	99%
CellCept	12%	11%	-46%	-50%
Pegasys	9%	17%	4%	11%
NeoRecormon/Epogin	-	-	-	-
Tarceva	5%	0%	-5%	8%
Xeloda	8%	11%	12%	18%
Lucentis	19%	21%	21%	21%
Bonviva/Boniva	12%	-17%	-10%	-14%
Xolair	13%	13%	11%	9%
Valcyte/Cymevene	5%	3%	8%	17%
Pulmozyme	24%	14%	4%	10%
Activase/TNKase	13%	49%	20%	38%
Nutropin	-1%	1%	2%	-6%
Xenical	-48%	-43%	-25%	-9%
Neutrogen	-	-	-	-
Rocephin	-89%	-97%	-11%	-
Madopar	-	-	-	-

7. Pharmaceuticals Division quarterly local product sales growth Japan in 2008 and 2009

	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008
Avastin	236%	147%	96%	59%
MabThera/Rituxan	9%	2%	4%	6%
Herceptin	73%	62%	42%	13%
Tamiflu	-2%	1207%	30977%	24671%
CellCept	10%	15%	8%	18%
Pegasys	39%	36%	30%	6%
NeoRecormon/Epogin	-16%	-8%	-1%	3%
Tarceva	699%	51%	27%	19%
Xeloda	81%	53%	27%	29%
Lucentis	-	-	-	-
Bonviva/Boniva	-	-	-	-
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Pulmozyme	-	-	-	-
Activase/TNKase	-	-	-	-
Nutropin	-	-	-	-
Xenical	-	-	-	-
Neutrogen	-13%	-22%	-13%	-10%
Rocephin	5%	-3%	-2%	-1%
Madopar	0%	7%	3%	3%

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World in 2008 and 2009

	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008	Q2 2009 vs. Q2 2008	Q3 2009 vs. Q3 2008
Avastin	52%	39%	33%	28%
MabThera/Rituxan	18%	6%	15%	13%
Herceptin	13%	13%	7%	11%
Tamiflu	6%	487%	1423%	10384%
CellCept	9%	3%	2%	-3%
Pegasys	1%	5%	10%	14%
NeoRecormon/Epogin	-4%	-15%	-10%	-11%
Tarceva	24%	20%	15%	14%
Xeloda	12%	4%	14%	5%
Lucentis	-	-	-	-
Bonviva/Boniva	47%	40%	21%	18%
Xolair	-	-	-	-
Valcyte/Cymevene	14%	11%	5%	-1%
Pulmozyme	2%	-9%	14%	5%
Activase/TNKase	11%	19%	0%	6%
Nutropin	-2%	-12%	0%	2%
Xenical	-7%	-11%	-8%	-15%
Neutrogin	-	-	-	-
Rocephin	-6%	-13%	3%	-3%
Madopar	4%	0%	-6%	1%

9. Top 20 Pharmaceuticals Division quarterly product sales in 2008 and 2009

CHF millions	Q3 2008	Q4 2008	Q1 2009	Q2 2009	Q3 2009
Avastin	1,351	1,505	1,485	1,605	1,594
MabThera/Rituxan	1,472	1,584	1,481	1,617	1,508
Herceptin	1,295	1,323	1,307	1,338	1,327
Tamiflu	101	181	401	609	994
CellCept	513	576	517	410	362
Pegasys	405	445	393	449	438
NeoRecormon/Epogin	427	455	378	411	391
Tarceva	298	330	320	323	319
Xeloda	307	331	296	330	326
Lucentis	246	274	279	294	296
Bonviva/Boniva	268	333	249	276	255
Xolair	145	156	152	161	157
Valcyte/Cymevene	143	149	131	143	148
Pulmozyme	120	139	120	128	125
Activase/TNKase	81	97	126	100	107
Nutropin	106	112	104	107	100
Xenical	126	112	103	106	98
Neutrogen	98	114	90	98	101
Rocephin	76	92	77	87	73
Madopar	77	80	68	72	71

10. Pharmaceuticals Division quarterly product sales in US in 2008 and 2009

CHF millions	Q3 2008	Q4 2008	Q1 2009	Q2 2009	Q3 2009
Avastin	754	841	810	883	851
MabThera/Rituxan	732	817	769	809	734
Herceptin	394	390	390	420	397
Tamiflu	96	70	15	302	189
CellCept	247	321	256	140	119
Pegasys	99	120	101	107	109
NeoRecormon/Epogin	-	-	-	-	-
Tarceva	117	136	128	125	126
Xeloda	111	131	106	118	131
Lucentis	246	274	279	294	296
Bonviva/Boniva	155	208	137	154	132
Xolair	145	156	152	161	157
Valcyte/Cymevene	66	76	60	72	77
Pulmozyme	69	83	75	73	76
Activase/TNKase	70	86	114	90	96
Nutropin	104	109	101	105	97
Xenical	9	8	8	10	9
Neutrogen	-	-	-	-	-
Rocephin	0	1	0	1	0
Madopar	-	-	-	-	-

11. Pharmaceuticals Division quarterly product sales in Japan in 2008 and 2009

CHF millions	Q3 2008	Q4 2008	Q1 2009	Q2 2009	Q3 2009
Avastin	57	82	82	100	102
MabThera/Rituxan	51	68	52	63	62
Herceptin	64	87	81	93	83
Tamiflu	1	71	250	50	351
CellCept	9	13	11	13	13
Pegasys	26	35	31	34	31
NeoRecormon/Epogin	111	142	115	131	131
Tarceva	11	16	15	17	16
Xeloda	13	17	15	18	19
Lucentis	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Activase/TNKase	-	-	-	-	-
Nutropin	-	-	-	-	-
Xenical	-	-	-	-	-
Neutrogen	98	114	90	98	101
Rocephin	14	19	15	17	16
Madopar	5	6	5	6	6

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World in 2008 and 2009

CHF millions	Q3 2008	Q4 2008	Q1 2009	Q2 2009	Q3 2009
Avastin	540	582	593	622	641
MabThera/Rituxan	689	699	660	745	712
Herceptin	837	846	836	825	847
Tamiflu	4	40	136	257	454
CellCept	257	242	250	257	230
Pegasys	280	290	261	308	298
NeoRecormon/Epogin	316	313	263	280	260
Tarceva	170	178	177	181	177
Xeloda	183	183	175	194	176
Lucentis	-	-	-	-	-
Bonviva/Boniva	113	125	112	122	123
Xolair	-	-	-	-	-
Valcyte/Cymevene	77	73	71	71	71
Pulmozyme	51	56	45	55	49
Activase/TNKase	11	11	12	10	11
Nutropin	2	3	3	2	3
Xenical	117	104	95	96	89
Neutrogen	-	-	-	-	-
Rocephin	62	72	62	69	57
Madopar	72	74	63	66	65